← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodySHOTFDACuratedFDABiologicMerckvedotin plus pembrolizumab …Approved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 100%임상시험 1334상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAbbVieApproved

adalimumab (Humira, Hyrimoz, Amjevita)

Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA · TNF-α

#TNF-#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 98.85%임상시험 420상태 APPROVED
AntibodySHOTFDACuratedFDABiologicJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 97%임상시험 342상태 APPROVED
AntibodyAHOTFDACuratedFDABiologicSanofiApproved

dupilumab (Dupixent)

Atopic dermatitis, asthma, CRSwNP, EoE · IL-4Rα

#IL-4R#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 0.45%임상시험 216상태 APPROVED
AntibodySHOTFDACuratedFDABiologicNovartisApproved

secukinumab (Cosentyx)

Psoriasis, psoriatic arthritis, ankylosing spondylitis · IL-17A

#IL-17A#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 78.1%임상시험 153상태 APPROVED
AntibodySHOTFDACuratedFDABiologicRocheApproved

ranibizumab (Lucentis, Byooviz, Cimerli)

Wet AMD, DME, RVO, myopic CNV · VEGF-A

#VEGF-A#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 68%임상시험 124상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAmgenApproved

etanercept (Enbrel, Erelzi)

RA, psoriasis, psoriatic arthritis, ankylosing spondylitis · TNF

#TNF#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 73.4%임상시험 117상태 APPROVED
AntibodySHOTFDACuratedFDABiologicJanssenApproved

ustekinumab (Stelara, Wezlana)

Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis · IL-12 / IL-23 (p40)

#IL-12IL-23p40#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 75%임상시험 116상태 APPROVED
AntibodySHOTFDACuratedFDABiologicRegeneronApproved

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

Wet AMD, DME, RVO, diabetic retinopathy · VEGF-A / VEGF-B / PIGF

#VEGF-AVEGF-BPIGF#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 66.4%임상시험 110상태 APPROVED
AntibodySHOTFDACuratedFDABiologicEli LillyApproved

lebrikizumab (Ebglyss, Lilly)

Atopic dermatitis · IL-13

#IL-13#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 75%임상시험 75상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAbbVieApproved

risankizumab (Skyrizi)

Psoriasis, psoriatic arthritis, Crohn's disease · IL-23 (p19)

#IL-23p19#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 90%임상시험 73상태 APPROVED
AntibodyHotRocheatApproved

Bevacizumab (Bevacizumab)

Colorectal Neoplasms · Recurrent Platinum-Sensitive Fallopian T

#RecurrentPlatinum-SensitiveFallo#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1131상태 RECRUITING
AntibodyHotRochevedotin, rituximab, cycloph…Approved

rituximab (rituximab)

Rheumatic Disease · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1091상태 DISCONTINUED
AntibodyHotEli LillyreleaseApproved

Cetuximab (Cetuximab)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 757상태 RECRUITING
AntibodyHotRochederuxtecan (Dato-DXd, Datro…Approved

trastuzumab (Herceptin)

Non Small Cell Lung Cancer; Colorectal Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#Antibody#Approved#인기#항체+5
효능 ORR 91.8%임상시험 676상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 648상태 RECRUITING
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 413상태 ACTIVE
AntibodyHotJanssenApproved

Infliximab (Infliximab)

Cytokine Release Syndrome; Recurrent Multiple Myeloma · Crohn Disease

#CrohnDisease#Antibody#Approved#인기#항체+5
효능 ORR 54.5%임상시험 283상태 ACTIVE
AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 204상태 DISCONTINUED
AntibodyAHotAstraZenecaderuxtecan 3Phase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#인기#항체+5
효능 ORR 84.6%임상시험 181상태 RECRUITING

1 / 92 페이지

← 이전다음 →